These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32264801)

  • 21. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
    Kaur AD; McQueen A; Jan S
    J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Petrakis I; Rosenheck R
    Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.
    Shcherbakova N; Tereso G; Spain J; Roose RJ
    Ann Pharmacother; 2018 May; 52(5):405-414. PubMed ID: 29302989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance.
    Mark TL; Hinde JM; Zarkin GA; Parish W; Kluckman M
    J Subst Abuse Treat; 2020 Sep; 116():108062. PubMed ID: 32741503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).
    D'Onofrio G; Edelman EJ; Hawk KF; Pantalon MV; Chawarski MC; Owens PH; Martel SH; VanVeldhuisen P; Oden N; Murphy SM; Huntley K; O'Connor PG; Fiellin DA
    Implement Sci; 2019 May; 14(1):48. PubMed ID: 31064390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States.
    Lo-Ciganic WH; Donohue JM; Kim JY; Krans EE; Jones BL; Kelley D; James AE; Jarlenski MP
    Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):80-89. PubMed ID: 30192041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic relationships between Veterans and buprenorphine providers and effects on treatment retention.
    Vakkalanka JP; Lund BC; Arndt S; Field W; Charlton M; Ward MM; Carnahan RM
    Health Serv Res; 2022 Apr; 57(2):392-402. PubMed ID: 34854083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
    Bagley SM; Larochelle MR; Xuan Z; Wang N; Patel A; Bernson D; Silverstein M; Hadland SE; Land T; Samet JH; Walley AY
    Ann Emerg Med; 2020 Jan; 75(1):29-38. PubMed ID: 31591014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Buprenorphine to Treat Opioid Use Disorder.
    Bartholow LAM; Pope J
    J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program.
    Payne BE; Klein JW; Simon CB; James JR; Jackson SL; Merrill JO; Zhuang R; Tsui JI
    Drug Alcohol Depend; 2019 Jul; 200():71-77. PubMed ID: 31103879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initiating buprenorphine treatment for hospitalized patients with opioid dependence: A case series.
    Suzuki J; DeVido J; Kalra I; Mittal L; Shah S; Zinser J; Weiss RD
    Am J Addict; 2015 Jan; 24(1):10-4. PubMed ID: 25823630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder.
    Carter JA; Dammerman R; Frost M
    J Med Econ; 2017 Aug; 20(8):893-901. PubMed ID: 28604141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
    Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
    Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.